Safety of dobutamine-atropine stress echocardiography in patients with suspected or proven coronary artery disease

Don Poldermans, Paolo M. Fioretti, Eric Boersma, Tamas Forster, Hero van Urk, Jan H. Cornel, Mariarosaria Arnese, Jos R.T.C.

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

The purpose of this study was to establish the safety of high-dose dobutamine-atropine stress echocardlography in patients with suspected or proven coronary artery disease. Six hundred fifty consecutive examinations were completed. Mean age of patients was 61 years; 300 had a previous myocardial infarction. Heart rate increased from 73 to 129 beats/min during stress testing, blood pressure did not change significantly (from 140/81 to 150/80 mm Hg). Atropine was added to dobutamine in 239 patients when no ischemia was induced with dobutamine alone and the peak heart rate was <85% of the theoretical maximal heart rate. Atropine was more frequently administered to patients taking β blockers (77 vs 27%, p <0.001). New wall motion abnormalities developed in 243 patients (37%). Significant or symptomatic cardiac tachyarrhythmias, or both, developed during 24 examinations: 1 patient developed ventricular fibrillation, 3 patients developed sustained ventricular tachycardia, 12 patients experienced nonsustained ventricular tachycardia (<10 beats) and 8 patients had paroxysmal atrial fibrillation. Cardiac arrhythmias were more frequent in patients with a history of ventricular arrhythmias (ventricular tachycardia and fibrillation) (odds ratio 9.9, 2.0 to 45) or left ventricular dysfunction at rest (wall motion score ≤1.12) (odds ratio 2.9, 1.1-7.6), but not associated with atropine addition. No death or myocardial infarction occurred. The full dose was not given to 13 patients despite absence of signs or markers of ischemia for limiting side effect, yielding an overall feasibility of the stress test of 98%/ Thus, dobutamine-atropine stress echocardiography is a relatively safe and highly feasible test with few adverse effects; its highest risk of significant arrhythmias occurs in patients with a history of ventricular arrhythmias or left ventricular dysfunction, or both.

Original languageEnglish
Pages (from-to)456-459
Number of pages4
JournalThe American Journal of Cardiology
Volume73
Issue number7
DOIs
Publication statusPublished - Mar 1 1994

    Fingerprint

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this